BCL2 and diffuse large B-cell lymphoma: A recent very large retrospective report on 879 R-CHOP-treated DLBCL cases convincingly showed CD5 to be an IPI (and bcl2 and pSTAT3)-independent prognosticator in DLBCL as well [53] and pointed out distinct clinico-pathological peculiarities of such patients such as increased age, bone marrow spread, poor performance status, and B symptoms.